All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
EHA 2018 | Interim phase II results of azacitidine for acute GvHD prophylaxis
On Saturday 16th June, during the 23rd Congress of EHA (European Hematology Association), Stockholm, Sweden, a poster (PS1471) by Mark Schroeder from Washington University School of Medicine, St. Louis, USA, et al. titled “A phase I/II trial of intravenous azacitidine for acute GvHD prophylaxis in patients undergoing matched unrelated stem cell transplantation: interim phase II results” was presented.
Based on previous studies assessing azacitidine in pre-clinical models, Schroeder and colleagues conducted a phase I/II study to evaluate the safety and efficacy of azacitidine after transplantation for the prevention of acute graft-versus-host disease (aGvHD) and relapse in patients undergoing matched unrelated stem cell transplantation.
Patients and methods:
- Median age = 59 years (range, 24–70)
- N = 35 of 46 patients received transplantation and study drug to date
- Patients received either myeloablative or reduced intensity conditioning without antithymocyte globulin
- Azacitidine was administered IV on Day +7 for five consecutive days and repeated every 28 days for a total of four cycles after allogeneic transplant
- GvHD prophylaxis: mini-methotrexate and tacrolimus
- The recommended phase II dose from phase I: 45 mg/m2
Key findings:
- Median follow up: 248 days (range, 27–891)
- Primary graft failure: one subject related to HHV6 infection
- Median ANC engraftment: 14 days
- Median platelet engraftment: 19 days (range, 10–NR)
- Acute GvHD incidence grade II – IV: 15 patients (43%)
- Acute GvHD incidence grade III/IV: 7 patients (20%)
- Incidence of steroid refractory GvHD: 7 patients
- Four patients have relapsed
- Most common non-hematologic grade 3 or 4 AEs: gastrointestinal toxicity, electrolyte abnormalities, and infections
In summary, azacitidine can be used safely as GvHD prophylaxis starting at day +7 after matched unrelated donor transplantation up to a dose of 45mg/m2. Phase II enrolment and follow up is ongoing.
References